Roche's vismodegib shrank tumors or healed lesions in 43% percent of clinical trial participants with locally advanced basal cell carcinoma and 30% of those with another advanced form of BCC, the drugmaker reported. Basal cell carcinoma is treatable with surgery, but advanced or widespread cases can cause severe disfigurement and death.

Full Story:

Related Summaries